333-333-3060 Psilocybin Training Curriculum Modules (1) "Historical, Traditional, and Contemporary Practices and Applications" module shall include: (a) Current and historical use of plant and fungal medicines in indigenous and western cultures; (b) The Controlled Substances Act and its effect on psilocybin research and drug policy; and (c) Overview of historical and recent academic research. (2) "Cultural Equity in relation to Psilocybin Services" module shall include the following subjects and their application during preparation, administration, and integration sessions: (a) Cultural equity, its relationship to health equity and social determinants of health; (b) Racial justice, including the impact of race and privilege on health outcomes and the impact of systemic racism on individuals and communities; (c) The impact of drug policy on individuals and communities; (d) History of systemic inequity, including systemic inequity in delivery of healthcare, mental health and behavioral health services; (e) Intergenerational trauma; and (f) Responsible Referral and Support (3) "Safety, Ethics, Law and Responsibilities" module shall include the following subjects and their application during preparation, administration, and integration sessions: (a) Awareness of facilitator’s personal bias, including examination of facilitator’s motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Ethical considerations relating to equity, privilege, bias and power; (B) Awareness of increased vulnerability associated with altered states of consciousness; (C) Appropriate use of touch and client consent to physical contact; (D) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (E) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (F) Financial conflicts of interest and duties to clients; and (G) Reasonable expectations regarding client outcomes. (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and conflict resolution. (4) "Psilocybin Pharmacology, Neuroscience, and Clinical Research" module shall include: (a) Pharmacodynamics and pharmacokinetics of psilocybin; (b) Drug and supplement interaction; (c) The metabolism of psilocybin and psilocybin products including concentration of psilocybin and psilocin in available psilocybin products; (d) The primary effects and mechanisms of action of psilocybin on the brain, including connectivity in the brain and activation of serotonin receptors; (e) Key areas of psilocybin research; and (f) Models of substance use, addiction, and recovery. (5) "Core Facilitation Skills" module shall include the following subjects and their application during preparation, administration, and integration sessions: (a) Client communication, empathy and rapport, including a nondirective facilitation approach, cultural attunement and a nonjudgmental disposition; (b) Response to psychological distress and creating a safe space for difficult emotional experiences; (c) Physical reactions and side effects of psilocybin; (d) Trauma informed care, including physiology of trauma, vicarious trauma, empathic stress and compassion fatigue; (e) Active monitoring of client-facilitator boundaries specifically boundaries related to consent and touch; (f) Identification and facilitation of a variety of subjective psilocybin experiences, including experiences relating to physiological sensations, cognitive, emotional and mystical states, and traumatic memories; (g) Appropriate modes of intervention, understanding when intervention is necessary, and when a client may need a higher level of care; (h) Recognizing and addressing adverse behavioral reactions and adverse medical reactions; and (i) Identification of the unique health, psychological and socio-cultural presented by persons with terminal illness; and awareness of the appropriate knowledge, skills and approach needed to provide safe facilitation to such persons in a manner consistent with client goals, values, heritage, and spiritual practices. (6) "Preparation and Orientation" module shall include: (a) Informed consent; (b) Client information form and intake interview, including discussion of client’s reasons for seeking psilocybin services; (c) Using the client information form to assist clients in identifying benefits of referral to specialized treatment services; (d) Facilitator role and the limits of facilitator’s scope of practice; (e) Trauma informed communication skills; (f) Identification of client safety concerns, including medical history, contra-indicated medication and psychological instability; (g) Appropriate strategies to discuss client safety concerns, including but not limited to identification of client’s support system; (h) Determination of whether a client should participate in an administration session; (i) Client directed safety planning to address identified safety concerns; (j) Boundaries between the facilitator and the client including use of touch; (k) Understanding of how racial and cultural dynamics affect interactions between client and facilitator; and (l) Historical and indigenous modalities of preparation. (7) "Administration" module shall include: (a) Dosing strategies and considerations, including: (A) Experiential differences relating to differing dosages; (B) Physiological considerations in relation to dosage; (C) Delivery mechanisms of psilocybin; and (D) Use of secondary doses. (b) Effectively working with challenging behaviors during an administration session, including: (A) Unexpected client disclosures; (B) Substance-induced psychosis; and (C) Suicidality. (c) Traumatic stress and its manifestation during a psilocybin experience and appropriate facilitator response, including: (A) Trauma’s relationship to the body; (B) Repressed trauma emerging during a psilocybin experience; (C) Trauma and traumatic stress resulting from systemic oppression; (D) Safety for trauma resolution and risks associated with re-traumatization; and (E) Protocols for ensuring facilitator safety and responding to emergencies. (d) "Set and Setting" including environmental considerations for administration session such as lighting sound and temperature; and (e) Completion of administration session. (8) "Integration" module shall include: (a) Identification of appropriate resources that may assist client with integration, including resources for: (A) Interpreting feelings and emotions experienced during administration session; (B) Facilitation of positive internal and external changes; (C) Enhancement of existing supportive relationship. (b) Identification of client safety concerns; (c) Facilitator scope of practice; and (d) Discussion of appropriate intervals between administration sessions and related safety concerns. (9) "Group Facilitation" module shall include: (a) Skills required to facilitate psilocybin group sessions, including, but not limited to: (A) Assessing client’s compatibility with group format; (B) Set and setting for group facilitation; (C) Facilitating group communications and dynamics, including strategies for working with multiple facilitators; (D) Group agreements, including confidentiality and safety; and (E) Identifying when a client within a group requires individual support, removal from a group, or additional intervention. (b) Group Preparation Sessions; (c) Group Integration Sessions; and (d) Regulatory requirements for group facilitation. Statutory/Other Authority: ORS 475A.235 & ORS 475A.380 Statutes/Other Implemented: ORS 475A.235 & ORS 475A.380 History: PH 58-2023, amend filed 12/21/2023, effective 01/01/2024 PH 74-2022, adopt filed 05/19/2022, effective 05/20/2022